title: [Syndrome of vena cava obstruction in oncology].
abstract: BACKGROUND
  Superior vena cava syndrome (SVCO) is caused by compression of superior vena cava and restriction of blood flow to the heart. The most common underlying condition in cancer patients is lung cancer or other malignancy expanding in the upper mediastinum. SVCO belongs to oncological emergencies and requires a prompt dia-gnostic work up and treatment.
  
  
  METHODS
  A 79year old man with a history of right sided stage IIIB nonsmall cell lung cancer, after two cycles of chemotherapy, was admitted to hospital with clinical signs of SVCO. The initial radiotherapy brought no relief of symptoms and due to deterioration of patients status during the treatment we proceeded to self expanding caval stent insertion. This was followed by immediate resolution of SVCO symptoms.
  
  
  METHODS
  In the second case we describe a 56year old female with a newly dia-gnosed diffuse large B cell lymphoma who presented with SVCO symptoms when referred to our outpatient chemotherapy department. She had no history of previous treatment and she complained of a rapid face and eyelid edema and intractable cough in the last two days. CT scan revealed mediastinal mass compressing the superior vena cava. Urgent antilymphoma chemotherapy (RCHOP schedule) was commenced and yielded quick resolution of her symp-toms.
  
  
  CONCLUSIONS
  Superior vena cava syndrome is a medical emergency in oncological patients usually caused by external compression of cava by lung cancer, lymphoma, other tumors, less frequently, from a thrombosis of indwelling central venous catheter. Multidiscip-linary cooperation among radiation and medical oncologists and interventional radiologists is needed in order to provide an early treatment without an undue delay.
authors: F
authors: F
authors: Kohútek
authors: I
authors: I
authors: Litvin
authors: M
authors: M
authors: Tamášová
authors: B
authors: B
authors: Bystrický
mesh_terms: D000368:Aged; D000970:Antineoplastic Agents / Q000009:adverse effects / Q000627:therapeutic use; D002289:Carcinoma, Non-Small-Cell Lung / Q000150:complications*; D005260:Female; D006801:Humans; D008175:Lung Neoplasms / Q000150:complications* / Q000188:drug therapy; D016393:Lymphoma, B-Cell / Q000150:complications* / Q000188:drug therapy; D008297:Male; D008875:Middle Aged; D015607:Stents; D013479:Superior Vena Cava Syndrome / Q000209:etiology* / Q000601:surgery; D016896:Treatment Outcome
chemical_list: D000970:Antineoplastic Agents